ResMed reports strong Q3 growth with a 21% increase in non-GAAP EPS and outlines a strategic acquisition of Noctrix. The company is also initiating significant share buybacks for the fourth quarter.
- FY 2026 gross margin target set at 62%-63%
- Q3 headline revenue increased 11% year-over-year